(0.36%) 5 118.23 points
(0.31%) 38 357 points
(0.37%) 15 987 points
(-1.04%) $82.98
(3.28%) $1.986
(0.03%) $2 348.00
(0.12%) $27.57
(3.16%) $951.25
(-0.07%) $0.934
(-0.04%) $11.02
(-0.30%) $0.798
(1.84%) $93.56
2 days till quarter result
(bmo 2024-05-01)
Expected move: +/- 7.61%
@ $7.87
发出时间: 22 Mar 2024 @ 02:10
回报率: -17.60%
上一信号: Mar 22 - 01:13
上一信号:
回报率: -0.76 %
Live Chart Being Loaded With Signals
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally...
Stats | |
---|---|
今日成交量 | 1.07M |
平均成交量 | 5.53M |
市值 | 1.51B |
EPS | $0 ( 2024-02-22 ) |
下一个收益日期 | ( $-0.130 ) 2024-05-01 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -21.62 |
ATR14 | $0.0240 (0.37%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-04-15 | Raab Michael | Sell | 7 500 | Common Stock |
2024-04-01 | Raab Michael | Sell | 1 518 | Common Stock |
2024-03-25 | Kelliher Mike | Buy | 205 000 | Stock Option (Right to Buy) |
2024-03-25 | Kelliher Mike | Buy | 160 000 | Common Stock |
2024-03-25 | Kelliher Mike | Buy | 0 |
INSIDER POWER |
---|
66.46 |
Last 99 transactions |
Buy: 4 000 095 | Sell: 852 364 |
音量 相关性
Ardelyx Inc 相关性 - 货币/商品
Ardelyx Inc 财务报表
Annual | 2023 |
营收: | $124.46M |
毛利润: | $106.66M (85.70 %) |
EPS: | $-0.300 |
FY | 2023 |
营收: | $124.46M |
毛利润: | $106.66M (85.70 %) |
EPS: | $-0.300 |
FY | 2022 |
营收: | $52.16M |
毛利润: | $48.04M (92.11 %) |
EPS: | $-0.420 |
FY | 2021 |
营收: | $10.10M |
毛利润: | $9.10M (90.10 %) |
EPS: | $-1.520 |
Financial Reports:
No articles found.
Ardelyx Inc
Ardelyx, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines to treat gastrointestinal and cardiorenal therapeutic areas in the United States and internationally. The company's lead product candidate is tenapanor, which has completed Phase III clinical trial for the treatment of patients with irritable bowel syndrome with constipation, as well as in Phase III clinical trial to control serum phosphorus in adult patients with chronic kidney disease (CKD)on dialysis, or hyperphosphatemia. It is also developing RDX013, a potassium secretagogue, for the treatment of elevated serum potassium, or hyperkalemia, a problem among certain patients with kidney and/or heart disease; and RDX020, an early-stage program in metabolic acidosis, a serious electrolyte disorder in patients with CKD. The company has agreements with Kyowa Kirin in Japan, Fosun Pharmaceutical Industrial Development Co. Ltd. in China, and Knight Therapeutics, Inc. in Canada for the development and commercialization of tenapanor in their respective territories. The company was formerly known as Nteryx, Inc. and changed its name to Ardelyx, Inc. in June 2008. Ardelyx, Inc. was incorporated in 2007 and is headquartered in Waltham, Massachusetts.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。